{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"25"}],"title":"EML4-ALK Variant 1"},{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}],"title":"EML4-ALK Variant 2"},{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"}],"title":"EML4-ALK Variant 3"},{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}],"title":"EML4-ALK Other"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}],"title":"ALK Rearrangement Other"},{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"36"}],"title":"ALK Rearrangement Not Detected"},{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"25"}],"title":"No cfDNA Detected"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Other (Sample failed analysis, uninformative, or not analyzed.)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}],"title":"EML4-ALK Variant 1"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"EML4-ALK Variant 2"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}],"title":"EML4-ALK Variant 3"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"title":"EML4-ALK Other"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"ALK Rearrangement Other"},{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"48"}],"title":"ALK Rearrangement Not Detected"},{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"58"}],"title":"No cfDNA Detected"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"title":"Other (Sample failed analysis, uninformative, or not analyzed.)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}],"title":"EML4-ALK Variant 1"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"EML4-ALK Variant 2"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}],"title":"EML4-ALK Variant 3"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"EML4-ALK Other"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"ALK Rearrangement Other"},{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"34"}],"title":"ALK Rearrangement Not Detected"},{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"35"}],"title":"No cfDNA Detected"},{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"title":"Other (Sample failed analysis, uninformative, or not analyzed.)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"Cycle 7 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"description":"The analysis of ALK fusion variant in plasma CNA was performed by NGS and the number of participants with fusion variants at Screening, Cycle 2 Day 1 and Cycle 7 Day 1 is presented here. In the table below, EML4-ALK is the abbreviation of echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase.","groups":[{"description":"Lorlatinib monotherapy at the recommended Phase 2 dose of 100 mg, was administered orally once daily (QD) at approximately the same time of the day on a continuous daily dosing schedule. Each treatment cycle was defined as 28 days. Treatment continued until confirmation of RECIST version 1.1 defined disease progression assessed by the blinded independent central review (unless clinical benefit was still achievable), participant refusal, participant lost to follow-up, unacceptable toxicity, death, or the study was terminated by the sponsor, whichever occurred first.","id":"OG000","title":"Lorlatinib"},{"description":"Crizotinib monotherapy at the registered dose of 250 mg, was administered orally twice daily (BID) at approximately the same time in the morning and evening (12 hours apart) on a continuous daily dosing schedule. Each treatment cycle was defined as 28 days. Treatment continued until confirmation of RECIST version 1.1 defined disease progression assessed by the blinded independent central review (unless clinical benefit was still achievable), participant refusal, participant lost to follow-up, unacceptable toxicity, death, or the study was terminated by the sponsor, whichever occurred first.","id":"OG001","title":"Crizotinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"\"Number of Participants Analyzed\" included all participants in the plasma CNA analysis population within each treatment group at screening. \"Number Analyzed\" included all participants in the plasma CNA analysis population within each treatment group at the specified visit.","reportingStatus":"POSTED","timeFrame":"at Screening, Cycle 2 Day 1 and Cycle 7 Day 1","title":"Number of Participant With ALK Fusion Variant in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1","type":"SECONDARY","unitOfMeasure":"Participants"}